Salvatore Privitera Sells 7,763 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 7,763 shares of AtriCure stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total value of $407,557.50. Following the sale, the insider directly owned 150,921 shares in the company, valued at $7,923,352.50. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AtriCure Trading Down 0.2%

ATRC stock opened at $52.46 on Friday. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $53.50. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $39.67 and its 200-day moving average is $32.70. The firm has a market cap of $2.67 billion, a P/E ratio of 249.82 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AtriCure

A number of hedge funds have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. bought a new stake in AtriCure during the 2nd quarter worth about $37,000. Harbor Investment Advisory LLC bought a new position in shares of AtriCure in the second quarter worth about $40,000. Allworth Financial LP acquired a new position in shares of AtriCure during the second quarter worth approximately $43,000. Smartleaf Asset Management LLC lifted its position in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares in the last quarter. Finally, Fifth Third Bancorp bought a new stake in shares of AtriCure during the first quarter valued at approximately $51,000. Institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ATRC. UBS Group reduced their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. BTIG Research increased their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Piper Sandler lifted their price target on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $52.00.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.